Modulation of immune responses – strategies for optimising vaccines

Bibliography

• JANEWAY CA JR, MEDZHITOV R: Innate immune recognition. Annu. Rev. Immunol. (2002) 20(1):197–216.
   PubMed Web of Science ®Google Scholar
• ••In this review article, the authors providean extensive description of the specific receptors (namely TLRs) and mechanisms involved in the innate immune response.
   Google Scholar
• CARL VS, BROWN-STEINKE K, NICKLIN MJH, SMITH MF JR: Toll-like receptor 2 and 4 (TLR2 and TLR4) agonists differentially regulate secretory interleukin-1 receptor antagonist gene expression in macrophages. J. Biol. Chem. (2002) 277(20):17448–17456.
   PubMed Web of Science ®Google Scholar
• SMITH MF JR, MITCHELL A, LI G et al: Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-{kappa}B activation and chemokine expression by epithelial cells. J. Biol. Chem. (2003) 278(35):32552–32560.
   PubMed Web of Science ®Google Scholar
• DARVILLE T, O& NEILL JM, ANDREWS CW JR et al.: Toll-like receptor-2, but not toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J. Immunol. (2003) 171(11):6187–6197.
   Google Scholar
• LEE J, CHUANG TH, REDECKE V et al.: Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. USA (2003) 100(11):6646–6651.
   PubMed Web of Science ®Google Scholar
• HEMMI H, KAISHO T, TAKEUCHI O et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. (2002) 3(2):196–200.
   PubMed Web of Science ®Google Scholar
• ROTHENFUSSER S, HORNUNG V, AYYOUB M et al.: CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood (2003) 103(6):2162–2169.
   PubMed Web of Science ®Google Scholar
• SEAMAN MS, PEYERL FW, JACKSON SS et al.: Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J. Viral. (2004) 78(1):206–215.
   PubMed Web of Science ®Google Scholar
• •This article describes how the timely administration of a plasmid DNA encoding a cytokine (namely IL-12) leads to the generation of different subsets of T lymphocytes, and the involvement of central versus effector memory subsets of the latter in the generation of a potent immune response in the context of a gp120 HIV DNA vaccination strategy.
   Google Scholar
• KIM JJ, YANG JS, DENTCHEV T, DANG K, WEINER DB: Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J. Interferon Cytokine Res. (2000) 20(5):487–498.
   PubMed Web of Science ®Google Scholar
• DISIS ML, SCHOLLER N, DAHLIN A et al.: Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. Mal. Cancer Ther. (2003) 2(10):995–1002.
   PubMed Web of Science ®Google Scholar
• BUKCZYNSKI J, WENT, ELLEFSEN K, GAULDIE J, WATTS TH: Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA (2004) 101(5):1291–1296.
   PubMed Web of Science ®Google Scholar
• •The costimulatory ligand 4-1BBL is described as an adjuvant in the induction of antiviral memory CD8 T cells with its potential use in combination with prime/boost vaccine strategies in the context of viral infections.
   Google Scholar
• AGADJANYAN MG, CHATTERGOON MA, HOLTERMAN MJ et al.: Costimulatory molecule immune enhancement in a plasmid vaccine model is regulated in part through the Ig constant-like domain of CD8O/86.j Immunol. (2003) 171(8):4311–4319.
   PubMed Web of Science ®Google Scholar
• •A series of chimaeric CD80 and CD86 costimulatory molecule constructs as well as respective deletion mutants were used as adjuvants to determine their immune activating potential in two DNA immunisation models. This study demonstrates that the lack of an Ig constant-like region in the CD80 molecule is critically important in immune activation.
   Google Scholar
• YUKI Y, KIYONO H: New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Viral. (2003) 13(5):293–310.
   PubMed Web of Science ®Google Scholar
• NOAD R, ROY P: Virus-like particles as immunogens. Trends Microbial. (2003) 11(9):438–444.
   PubMed Web of Science ®Google Scholar
• JALAVA K, EKO FO, RIEDMANN E, LUBITZ W: Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev. Vaccines (2003) 2(1):45–51.
   PubMedGoogle Scholar
• ROEDERER M, KOUP RA: Optimized determination of T cell epitope responses. J. Immunol. Methods (2003) 274(1-2):221–228.
   PubMed Web of Science ®Google Scholar
• DE GROOT AS, SBAI H, AUBIN CS, MCMURRY J, MARTIN W: Immuno-informatics: mining genomes for vaccine components. Immunol. Cell Biol. (2002) 80(3):255–269.
   PubMed Web of Science ®Google Scholar
• MARTIN W, SBAI H, DE GROOT AS: Bioinformatics tools for identifying class I-restricted epitopes. Methods (2003) 29(3):289–298.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, NAKAGAWA Y, PENDLETON CD et al.: Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science (1992) 255(5042):333–336.
   PubMed Web of Science ®Google Scholar
• BERZOFSKY JA, AHLERS JD, BELYAKOV IM: Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. (2001) 1(3):209–219.
   PubMed Web of Science ®Google Scholar
• SLANSKY JE, RATTIS FM, BOYD LF et al.: Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity (2000) 13(4):529–538.
   PubMed Web of Science ®Google Scholar
• •This article discusses the involvement of altered peptide ligands in the generation of more potent immune responses in the context of tumour vaccines, thus stressing the importance of the latter in the careful design of succesful vaccination strategies.
   Google Scholar
• BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392:245–252.
   PubMed Web of Science ®Google Scholar
• MARTIN-FONTECHA A, SEBASTIANI S, HOPKEN UE et al.: Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med. (2003) 198(4):615–621.
   PubMed Web of Science ®Google Scholar
• KAECH SM, WHERRY EJ, AHMED R: Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. (2002) 2(4):251–262.
   PubMed Web of Science ®Google Scholar
• ••This review article highlights theimportance of commitment signals leading to effector or memory T cell generation and the implications in vaccine strategy optimisation.
   Google Scholar